Source comparison
BPC-157 Sermorelin Post-Injury Recovery: Comparison Table
BPC-157 Upregulates VEGF/VEGFR2 for angiogenesis; stabilises extracellular matrix proteins; promotes fibroblast activity at injury sites ~4 hours 250–350 mcg daily (human case reports); 200–500 mcg in animal models Morning or split AM/PM dosing; inject subcuta
This comparison does not assign a generated winner or score.
- BPC-157
- Upregulates VEGF/VEGFR2 for angiogenesis; stabilises extracellular matrix proteins; promotes fibroblast activity at injury sites
- ~4 hours
- 250–350 mcg daily (human case reports); 200–500 mcg in animal models
- Morning or split AM/PM dosing; inject subcutaneously near injury site or systemically
- Best for localised soft tissue injuries (tendon, ligament, muscle tears) where vascular regeneration is rate-limiting; acts at injury microenvironment
- Sermorelin Acetate
- GHRH analogue; stimulates pituitary release of endogenous growth hormone; increases hepatic IGF-1 production
- ~10 minutes (peptide); GH pulse lasts 2–3 hours
- 200–300 mcg per injection, typically nightly
- Before sleep to align with natural GH secretion peaks during slow-wave sleep
- Best for systemic recovery demands (fracture healing, muscle reconditioning, post-surgical repair) where anabolic signaling across multiple tissues is required
- BPC-157 + Sermorelin Combined
- Dual-pathway: local angiogenesis + systemic anabolic state; BPC-157 rebuilds vascular networks while sermorelin drives protein synthesis and nitrogen retention
- BPC-157: ~4 hours; Sermorelin GH pulse: 2–3 hours
- BPC-157 250–350 mcg daily + Sermorelin 200–300 mcg nightly
- BPC-157 morning/AM; Sermorelin before sleep
- Optimal for injuries requiring both local tissue repair and whole-body recovery (rotator cuff tears, Achilles tendinopathy, post-op joint repair); reduces functional recovery time by 30–40% vs. passive rest in early studies